1. トップ >
  2. Medical Affairs Website >
  3. 神経領域Publication一覧

神経領域Publication一覧

　毎月更新予定
（最終更新：2024/10）

こちらには弊社社員が著者に含まれる論文や、弊社から資金提供・原薬提供などを行った研究論文を掲載しています。

神経領域

2024開く

    ＜英文＞

  • Post hoc analysis of the characteristics and treatment needs of patients with dementia with Lewy bodies (DLB) and their caregivers and their physicians' awareness of those treatment needs according to the duration after diagnosis of DLB.

    M. IKEDA et al., Int J Geriatr Psychiatry. 2024;39(8):e6122.

  • Factors Associated with Quality of Life in Patients with Dementia with Lewy Bodies: Additional Analysis of a Cross-Sectional Study.

    S.Toya et al. J Alzheimers Dis. 2024;100(2):525-538. doi: 10.3233/JAD-231302.

  • Differences in the treatment needs of patients with dementia with Lewy bodies and their caregivers and differences in their physicians’ awareness of those treatment needs according to the clinical department visited by the patients: A subanalysis of an observational survey study.

    M. Ikeda et al. Alzheimers Res Ther. 2024 Mar 14;16(1):59.

  • Eating problems in people with dementia with Lewy bodies: associations with various symptoms, and the physician's understanding.

    S. Shinagawa et al., International Psychogeriatrics 2024 Feb 26:1-11.

  • Neuroinflammation following anti-parkinsonian drugs in early Parkinson’s disease: a longitudinal PET study.

    T. Terada et al, Scientific Reports 2024 Feb 27;14(1):4708.

    • ＜和文＞

2023開く

    ＜英文＞

  • Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study

    M. Ikeda et al. J Alzheimers Dis. 2023;95(1):251-264.

  • Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.

    Sano H et al. Front Aging Neurosci. 2023 Jun 27;15:1221341.

  • Questionnaire survey of satisfaction with medication for five symptom domains of dementia with Lewy bodies among patients, their caregivers, and their attending physicians.

    S Toya et al. Psychogeriatrics. 2023 Jun 25.

  • Correction: Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan.

    M.Hashimoto et al. Alzheimers Res Ther. 2023 Jan 5;15(1):4.

    • ＜和文＞

  • Lewy小体型認知症に伴うパーキンソニズムに対するゾニサミド一般使用成績調査：日常診療下でのゾニサミド25mg/日の安全性および有効性の検討

    谷　俊輔 他　脳神経内科, 99巻2号 P.259-273

  • レビー小体型認知症の各症状に対するエキスパート　医師による薬剤処方の実態調査

    橋本 衛 他. Dementia Japan. 2023 37-3

2022開く

    ＜英文＞

  • Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan.

    M.Hashimoto et al. Alzheimers Res Ther. 2022 Dec 15;14(1):188.

  • Pretreatment with Zonisamide Mitigates Oxaliplatin-Induced Toxicity in Rat DRG Neurons and DRG Neuron-Schwann Cell Co-Cultures.

    S.Takaku et al. Int J Mol Sci. 2022 Sep 1;23(17):9983.

  • Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide.

    T.Naito et al. J Neurol Neurosurg Psychiatry. 2022 May;93(5):509-512.

  • Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.

    T.Odawara et al. Am J Geriatr Psychiatry. 2022 Mar;30(3):314-328.

    • ＜和文＞

  • パーキンソニズムを有するレビー小体型認知症患者を対象としたゾニサミド 25 mg/日を長期投与時の有効性と安全性　ー第三相試験のポストホック解析ー

    小田原俊成ら　Dementia Japan. 2022;36(3):496-508.

2021開く

    ＜英文＞

  • Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials.

    Y.Tsuboi et al. eNeurologicalSci. 2021 Dec 7;26:100384.

  • Zonisamide improves wearing off in Parkinson‘s disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.

    Y.Tsuboi et al. J Neurol Sci. 2021 Nov15;430:120026.

  • Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.

    K.Hasegawa et al. J Alzheimers Dis. 2021;79:627-637.

    • ＜和文＞

  • ドパミンアゴニストからゾニサミドへの切り替えによるパーキンソン病患者の精神症状及び運動症状への影響

    阿部隆志ら　臨床神経学,2021, 61巻7号 P.449-455

2020開く

    ＜英文＞

  • Zonisamide promotes survival of human-induced pluripotent stem cell-derived dopaminergic neurons in the striatum of female rats.

    Y.Miyawaki et al. J Neurosci Res. 2020 Aug;98(8):1575-1587.

  • Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.

    Pei-Chieng Cha et al. J Hum Genet. 2020 Aug;65(8):693-704.

  • Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.

    M.Murata et al. Parkinsonism Relat Disord. 2020 Jul;76:91-97.

  • Zonisamide enhances neurite outgrowth from adult rat dorsal root ganglion neurons, but not proliferation or migration of Schwann cells.

    S.Takaku et al. Histochem Cell Biol. 2020 Mar;153(3):177-184.

  • Zonisamide for Treating Parkinson’s Disease.

    R.Hanajima et al.NeuroPsychopharmacotherapy, 2020 p.1-9

  • Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model.

    S.Kanbara et al. Sci Rep. 2020 Aug 4;10(1):13138.

  • Zonisamide ameliorates neuropathic pain partly by suppressing microglial activation in the spinal cord in a mouse model.

    H.Koshimizu et al. Life Sci. 2020 Dec 15;263:118577.

2019開く

    ＜英文＞

  • Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.

    H.Iwaki et al. J Neurol Sci. 2019 Jul 15;402:145-152.

  • A survey of doctors on diagnosis and treatment of dementia with Lewy bodies: examination and treatment of behavioural and psychological symptoms.

    T.Odawara et al. Psychogeriatrics. 2019 Jul;19(4):310-319.

  • Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies.

    Y.Manabe et al. Psychogeriatrics. 2019 Jul;19(4):345-354.

  • The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.

    H.Sano et al. Neurochem Int. 2019 Mar;124:171-180.

    • ＜和文＞

  • Wearing-offを呈するParkinson病患者の実臨床下での処方状況およびゾニサミド50mg/日の安全性・有効性の検討

    谷俊輔ら　脳神経内科, 2019, 91巻3号 P.378-389

2018開く

    ＜英文＞

  • Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.

    K.Ikeda et al. J Neurol Sci.2018 Aug 15;391:5-9.

  • Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.

    M.Murata et al. Neurology. 2018 Feb 20;90(8):e664-e672.

  • Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.

    S.Ueno et al. Cells. 2018 Dec 29;8(1):14.

  • Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease.

    H.Nishijima et al. Parkinsons Dis. 2018 Dec 18;2018:8626783

2017開く

    ＜英文＞

  • Overcoming Obstacles to Drug Repositioning in Japan.

    Y.Nishimura et al. Front Pharmacol. 2017 Oct 11;8:729.

  • Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.

    M.Uemura et al. Neurosci Res. 2017 Nov;124:25-32.

  • Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.

    M.Oki et al. Neurosci Res. 2017 Sep;122:45-50.

  • Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.

    S. Matsunaga et al. J Alzheimer's Dis. 2017;56(4):1229-1239

    • ＜和文＞

  • Wearing-off現象を発現したパーキンソン病患者に対するゾニサミド50mgの安全性および有効性の検討　長期使用に関する特定使用成績調査の中間報告

    右橋千秋ら　新薬と臨牀, 2017, 66巻12号 P.1493-1509

2016開く

    ＜英文＞

  • Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease.

    M.Murata et al. Neurology and Clinical Neuroscience, 2016, 4:10–15

2015開く

    ＜英文＞

  • Influence of Zonisamide on the LTP-like Effect Induced by Quadripulse Transcranial Magnetic Stimulation (QPS).

    N.Tanaka et al. Brain Stimul. 2015 Nov-Dec;8(6):1220-2.

  • Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.

    M.Murata et al. Mov Disord. 2015 Sep;30(10):1343-50.

  • Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.

    S.Tsujii et al. Eur J Pharmacol. 2015 Jan 5;746:301-7

  • Modulation of endoplasmic reticulum stress in Parkinson's disease.

    S.Tsujii et al. Eur J Pharmacol. 2015 Oct 15;765:154-6.

  • Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve Regeneration In Vitro and in a Mouse Model.

    H.Yagi et al. PLoS One. 2015 Nov 16;10(11):e0142786.

  • Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.

    H.Sano et al. J Neurochem. 2015 Jul;134(2):371-81.

2014開く

    ＜英文＞

  • Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway.

    K.Fukuyama et al. Neuropharmacology. 2014 Jan;76 Pt A:137-45.

  • Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.

    S.Arawaka et al. PLoS One. 2014 Feb 20;9(2):e89076

    • ＜和文＞

  • パーキンソン病治療薬トレリーフ(ゾニサミド)について

    村橋豊ら　別冊Bio Clinica, 慢性炎症と疾患, 2014, 3巻1号 P.150-155